The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Abby Jones’ first stop of the day delivering medication was the home of 90-year-old Sarah Campbell Kier. “Come in!” yelled ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Industry group PhRMA slams Medicare's Inflation Reduction Act, alleging failure to regulate PBMs and insurers as Medicare ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...

The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...